Daily Newsletter

11 October 2023

Daily Newsletter

11 October 2023

UPS Healthcare debuts healthcare logistics service in Europe

The logistics service is taking another step in becoming a leader in healthcare and pharmaceutical logistics.

Jenna Philpott October 10 2023

UPS Healthcare has announced the launch of UPS Pickup Point locations, a new reverse logistics service for health laboratory customers, across the UK, Germany, Italy, France, and Spain.

The Pickup Points aim to combat the challenges that healthcare-related logistics present with the increase in new medicine development. Many healthcare facilities have samples coming in from various locations with different time schedules.

UPS Pickup Points locations create a reverse logistics solution by providing collection confirmation and visibility of time-sensitive specimens. The service provides a more streamlined solution for healthcare companies by decreasing the number of collection sites and improving reliability, control, and the shipment of samples to a central lab.

President of UPS Healthcare John Bolla said: “As we tackle global healthcare challenges and the needs of individual patients, every specimen counts. Connected to our global network, UPS Pickup Point locations provide our customers with unique new solutions to manage the reverse logistics of getting specimens to labs.”

In September, UPS announced its plans to acquire MNX Global Logistics by the end of this year. MNX provides transportation solutions to customers in the biopharmaceutical and life sciences sectors. The company handles temperature-sensitive cell and gene therapies using same-day ground services and transports radiopharmaceuticals via air charters.

Sectors such as cell and gene therapies rely on high-quality logistics due to the complex supply chains, as the therapy must be available as soon as the patient requires it. The rise in temperature-controlled products has increased the demand for cold-chain pharmaceutical logistics companies.

Significant opportunities and risks for disease-modifying therapies (DMTs) entering the PD market

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close